This website is for Healthcare Professionals only.

A subcutaneous T-cell engaging CD3xCD20 bispecific antibody^1,2

Specifically engineered for high-specificity binding and minimal off-target effects^1,2

By binding CD20-expressing B cells and CD3-expressing T cells, TEPKINLY induces specific T-cell activation and T-cell–mediated killing of the CD20-expressing cancer cells.³

Efficient T-cell–mediated cytotoxicity was achieved even with very low levels of CD20 expression.²

In preclinical studies, TEPKINLY demonstrated specific and highly potent antitumour activity in vitro and in vivo.²

Unlike conventional CD20 monoclonal antibodies, direct effector mechanisms are prevented by the silenced Fc region.^2,4

CD3=cluster of differentiation 3; CD20=cluster of differentiation 20; Fc region=fragment crystallization region.

TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.³

References: 1. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. Published online December 22, 2022. doi:10.1200/JCO.22.01725 2. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. doi:10.1016/j.ebiom.2019.102625 3. TEPKINLY Summary of Product Characteristics. AbbVie Inc. 4. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8

ALL-EPCOR-230034